Ampligen® (rintatolimod)
Locally Advanced Pancreatic Cancer
Key Facts
About AIM ImmunoTech
AIM ImmunoTech is dedicated to advancing immunology solutions with its lead immuno-modulator, Ampligen. The company has a diversified pipeline targeting oncology, viral diseases like COVID-19, and immune disorders such as ME/CFS, with clinical programs underway at major research centers. Its strategic focus is on developing Ampligen as a combinational therapy for solid tumors and addressing post-viral syndromes, positioning it in several large and growing therapeutic markets.
View full company profileAbout AIM ImmunoTech
AIM ImmunoTech is dedicated to advancing immunology solutions with its lead immuno-modulator, Ampligen. The company has a diversified pipeline targeting oncology, viral diseases like COVID-19, and immune disorders such as ME/CFS, with clinical programs underway at major research centers. Its strategic focus is on developing Ampligen as a combinational therapy for solid tumors and addressing post-viral syndromes, positioning it in several large and growing therapeutic markets.
View full company profileAbout AIM ImmunoTech
AIM ImmunoTech is dedicated to advancing immunology solutions with its lead immuno-modulator, Ampligen. The company has a diversified pipeline targeting oncology, viral diseases like COVID-19, and immune disorders such as ME/CFS, with clinical programs underway at major research centers. Its strategic focus is on developing Ampligen as a combinational therapy for solid tumors and addressing post-viral syndromes, positioning it in several large and growing therapeutic markets.
View full company profileAbout AIM ImmunoTech
AIM ImmunoTech is dedicated to advancing immunology solutions with its lead immuno-modulator, Ampligen. The company has a diversified pipeline targeting oncology, viral diseases like COVID-19, and immune disorders such as ME/CFS, with clinical programs underway at major research centers. Its strategic focus is on developing Ampligen as a combinational therapy for solid tumors and addressing post-viral syndromes, positioning it in several large and growing therapeutic markets.
View full company profileAbout AIM ImmunoTech
AIM ImmunoTech is dedicated to advancing immunology solutions with its lead immuno-modulator, Ampligen. The company has a diversified pipeline targeting oncology, viral diseases like COVID-19, and immune disorders such as ME/CFS, with clinical programs underway at major research centers. Its strategic focus is on developing Ampligen as a combinational therapy for solid tumors and addressing post-viral syndromes, positioning it in several large and growing therapeutic markets.
View full company profileAbout AIM ImmunoTech
AIM ImmunoTech is dedicated to advancing immunology solutions with its lead immuno-modulator, Ampligen. The company has a diversified pipeline targeting oncology, viral diseases like COVID-19, and immune disorders such as ME/CFS, with clinical programs underway at major research centers. Its strategic focus is on developing Ampligen as a combinational therapy for solid tumors and addressing post-viral syndromes, positioning it in several large and growing therapeutic markets.
View full company profile